JP2018510864A5 - - Google Patents

Download PDF

Info

Publication number
JP2018510864A5
JP2018510864A5 JP2017547459A JP2017547459A JP2018510864A5 JP 2018510864 A5 JP2018510864 A5 JP 2018510864A5 JP 2017547459 A JP2017547459 A JP 2017547459A JP 2017547459 A JP2017547459 A JP 2017547459A JP 2018510864 A5 JP2018510864 A5 JP 2018510864A5
Authority
JP
Japan
Prior art keywords
seq
amino acids
antibody
terminal extension
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017547459A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018510864A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/020192 external-priority patent/WO2016144608A1/en
Publication of JP2018510864A publication Critical patent/JP2018510864A/ja
Publication of JP2018510864A5 publication Critical patent/JP2018510864A5/ja
Pending legal-status Critical Current

Links

JP2017547459A 2015-03-10 2016-03-01 トランスグルタミナーゼによって結合可能な抗体およびそれによって製造される結合体 Pending JP2018510864A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562130673P 2015-03-10 2015-03-10
US62/130,673 2015-03-10
PCT/US2016/020192 WO2016144608A1 (en) 2015-03-10 2016-03-01 Antibodies conjugatable by transglutaminase and conjugates made therefrom

Publications (2)

Publication Number Publication Date
JP2018510864A JP2018510864A (ja) 2018-04-19
JP2018510864A5 true JP2018510864A5 (enExample) 2019-04-11

Family

ID=55538626

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017547459A Pending JP2018510864A (ja) 2015-03-10 2016-03-01 トランスグルタミナーゼによって結合可能な抗体およびそれによって製造される結合体

Country Status (6)

Country Link
US (1) US10676773B2 (enExample)
EP (1) EP3268048B1 (enExample)
JP (1) JP2018510864A (enExample)
CN (1) CN107406496A (enExample)
ES (1) ES2736106T3 (enExample)
WO (1) WO2016144608A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3419670A2 (en) * 2016-02-26 2019-01-02 Regeneron Pharmaceuticals, Inc. Optimized transglutaminase site-specific antibody conjugation
EP3272864A1 (en) 2016-07-20 2018-01-24 Paul Scherrer Institut Solid-phase immobilization of microbial transglutaminase mtg on microbeads for protein conjugation
WO2018075842A1 (en) 2016-10-20 2018-04-26 Bristol-Myers Squibb Company Condensed benzodiazepine derivatives and conjugates made therefrom
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
US10472361B2 (en) 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
US10487084B2 (en) 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
US10457681B2 (en) 2017-08-16 2019-10-29 Bristol_Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
NZ762376A (en) 2017-09-19 2022-08-26 Scherrer Inst Paul Transglutaminase conjugation method and linker
US11485741B2 (en) 2018-04-24 2022-11-01 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (TLR7) agonists
EP3801629A1 (en) 2018-05-29 2021-04-14 Bristol-Myers Squibb Company Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
HUE062089T2 (hu) * 2018-11-30 2023-09-28 Rao Naik Chetana Antitest, amely tartalmaz glutamintartalmú könnyû lánc C-terminális meghosszabbítást, annak konjugátumai, és eljárások és felhasználások
US12478686B2 (en) 2018-12-12 2025-11-25 Bristol-Myers Squibb Company Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses
CA3128571A1 (en) 2019-03-19 2020-09-24 Paul Scherrer Institut Transglutaminase conjugation method with a glycine based linker
CA3183613A1 (en) 2020-05-19 2021-11-25 Les Laboratoires Servier Para-amino-benzyl linkers, process for their preparation and their use in conjugates
CN116406302A (zh) 2020-09-18 2023-07-07 阿拉里斯生物技术股份公司 用基于氨基酸的接头的谷氨酰胺转胺酶缀合方法
PE20231512A1 (es) 2020-10-25 2023-09-26 Araris Biotech Ag Medios y metodos para producir conjugados de ligador-anticuerpo
JPWO2023054706A1 (enExample) * 2021-09-30 2023-04-06
WO2023072934A1 (en) 2021-10-25 2023-05-04 Araris Biotech Ag Methods for producing antibody-linker conjugates
CN118742328A (zh) 2022-02-22 2024-10-01 阿拉里斯生物技术股份公司 包含两个或更多个有效载荷的肽接头
US20230408497A1 (en) * 2022-06-20 2023-12-21 Sysmex Corporation Labeled polypeptide, modified polypeptide, production method for these polypeptides, reagent containing these polypeptides, and measurement method for target substance
WO2025082990A1 (en) 2023-10-15 2025-04-24 Araris Biotech Ag Antibody-drug conjugates using two different types of topoisomerase i inhibitors
US20250282786A1 (en) 2024-03-05 2025-09-11 Bristol-Myers Squibb Company Tricyclic TLR7 Agonists and Uses Thereof
WO2025188693A1 (en) 2024-03-05 2025-09-12 Bristol-Myers Squibb Company Bicyclic tlr7 agonists and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6322996B1 (en) 1994-08-23 2001-11-27 Drug Delivery System Institute, Ltd. Protein modification method
WO1997012862A1 (en) 1995-10-03 1997-04-10 The Scripps Research Institute Cbi analogs of cc-1065 and the duocarmycins
JP2003527561A (ja) 1999-01-22 2003-09-16 スミスクライン・ビーチャム・コーポレイション 蛋白の部位特異的標識化方法およびそのための使用
JP4118462B2 (ja) 1999-07-19 2008-07-16 株式会社リコー 携帯電子機器
CN100522999C (zh) * 2002-02-14 2009-08-05 免疫医疗公司 抗cd20抗体及其融合蛋白和使用方法
EP2281577B1 (en) 2003-05-14 2016-11-16 ImmunoGen, Inc. Drug conjugate composition
US20070184537A1 (en) 2003-06-03 2007-08-09 Paul Scherrer Institut Method for the linkage of bifunctional chelating agents and (radioactive) transition metal complexes to proteins and peptides
NZ583292A (en) 2003-11-06 2012-03-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
US7778814B2 (en) 2004-03-30 2010-08-17 Siemens Aktiengesellschaft Method and device for simulating an automation system
WO2007038868A2 (en) 2005-10-03 2007-04-12 The University Of British Columbia Novel enediyne compound and uses thereof
PE20080316A1 (es) 2006-05-25 2008-04-10 Bristol Myers Squibb Co Compuestos de aziridinil-epotilona
AR062448A1 (es) 2006-05-25 2008-11-12 Endocyte Inc Conjugados de analogos de aziridinil-epotilona y composiciones farmaceuticas que comprenden los mismos
US20100150950A1 (en) 2006-12-14 2010-06-17 Medarex, Inc. Human antibodies that bind cd70 and uses thereof
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
EP2185188B1 (en) 2007-08-22 2014-08-06 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
KR101554753B1 (ko) 2007-10-01 2015-09-22 브리스톨-마이어스 스큅 컴퍼니 메소텔린에 결합하는 인간 항체 및 이의 용도
JPWO2010002042A1 (ja) 2008-07-04 2011-12-22 国立大学法人九州大学 タンパク質ラベル化用酵素基質
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
CN102971329B (zh) 2010-04-15 2016-06-29 麦迪穆有限责任公司 用于治疗增殖性疾病的吡咯并苯并二氮杂卓
NZ602932A (en) 2010-04-15 2014-08-29 Seattle Genetics Inc Targeted pyrrolobenzodiazapine conjugates
CA2813411C (en) * 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
CN103987718A (zh) 2011-09-20 2014-08-13 斯皮罗根有限公司 作为非对称二聚体pbd化合物用于内含在靶向结合物中的吡咯并苯并二氮杂卓
BR112014013526A8 (pt) * 2011-12-05 2017-06-13 Igenica Biotherapeutics Inc conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados
WO2013092998A1 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of antibodies
TW201336851A (zh) 2012-02-13 2013-09-16 必治妥美雅史谷比公司 烯二炔化合物,其共軛物及彼等之用途與方法
EP2854845B1 (en) * 2012-06-01 2018-03-28 IBC Pharmaceuticals, Inc. Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy
WO2014031646A2 (en) * 2012-08-20 2014-02-27 Gliknik Inc. Molecules with antigen binding and polyvalent fc gamma receptor binding activity
RU2618523C2 (ru) * 2012-11-05 2017-05-04 Пфайзер Инк. Аналоги сплицеостатина
WO2014072482A1 (en) 2012-11-09 2014-05-15 Innate Pharma Recognition tags for tgase-mediated conjugation
SI2956173T1 (sl) 2013-02-14 2017-06-30 Bristol-Myers Squibb Company Spojine tubulizina, postopki pridobivanja in uporaba
WO2014202773A1 (en) 2013-06-20 2014-12-24 Innate Pharma Enzymatic conjugation of polypeptides
KR20160042871A (ko) 2013-06-21 2016-04-20 이나뜨 파르마, 에스.아. 폴리펩티드의 효소적 콘쥬게이션

Similar Documents

Publication Publication Date Title
JP2018510864A5 (enExample)
US10696676B2 (en) Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
JP2016536342A5 (enExample)
JP2019520352A5 (enExample)
AU2020219803B2 (en) Nanoparticle-based influenza virus vaccines and uses thereof
TW201920182A (zh) 具有吡啶或吡部分之類鐸受體7(tlr7)促效劑,其結合物及其等之方法及用途
TW201920181A (zh) 具有經雜原子連接之芳香族部分之類鐸受體7(tlr7)促效劑,其結合物及其等之方法及用途
JP2011511773A5 (enExample)
JP2011500725A5 (enExample)
TWI455946B (zh) 抗磷脂醯肌醇蛋白聚糖3抗體
CN109475641A (zh) 利用固相固定的微生物转谷氨酰胺酶mtg和溶液中的mtg对抗体赖氨酸残基的位点特异性缀合
KR20200041914A (ko) 면역자극제 톨-유사 수용체 7 (tlr7) 효능제로서의 6-아미노-7,9-디히드로-8h-퓨린-8-온 유도체
RU2015100656A (ru) Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения
JP2015529208A5 (enExample)
JP2019519490A5 (enExample)
JP2017518304A5 (enExample)
JP2019524645A5 (enExample)
JP2017526350A5 (enExample)
JP2011036254A5 (enExample)
JP2021121590A5 (enExample)
JP2018530331A5 (enExample)
JP2015527366A5 (enExample)
JP2018193386A5 (enExample)
JP2018529321A5 (enExample)
HRP20190878T1 (hr) Modificirane aminokiseline koje sadrže azidnu grupu